

RECEIVED
CENTRAL FAX CENTER**JAN 23 2006**
GlaxoSmithKline**FAX**


To Attn: Examiner A. Holleran, Group 1643
.....
Company USPTO
.....
Fax (571) 273-8300
.....
From Patty Wilson
.....
Tel 1-919-483-1007; Facsimile: 1-919-483-7977
.....
E-mail patricia.f.wilson@gsk.com
.....
Date January 23, 2006 **Pages including cover** 14
.....
Subject Application of: Cheever et al.
U.S. Serial No.: 09/493,480
Attorney Docket No. CRX113US
.....

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709Tel: 919 483 2100
www.gsk.com

Attached: Amendment Transmittal (2 pgs);
Amendment (12 pgs).

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile
transmitted on January 23, 2006.


Patty Wilson

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.


COMBINED AMENDMENT & PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) (Large Entity)					Docket No. CRX113US	
In Re Application Of: Martin A. CHEEVER et al.						
Application No. 09/493,480	Filing Date 1/28/2000	Examiner Anne Holleran	Customer No. 23347	Group Art Unit 1643	Confirmation No. 2303	
Invention: HER-2/New Fusion Proteins				RECEIVED CENTRAL FAX CENTER JAN 23 2006		
<u>COMMISSIONER FOR PATENTS:</u> This is a combined amendment and petition under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the Office Action of <u>1/12/2005</u> in the above-identified application. <div style="text-align: center; font-size: small;">Date</div> The requested extension is as follows (check time period desired): <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <input type="checkbox"/> One month <input type="checkbox"/> Two months <input checked="" type="checkbox"/> Three months <input type="checkbox"/> Four months <input type="checkbox"/> Five months </div> <div style="display: flex; justify-content: space-between; margin-top: 10px;"> from: <u>11/12/2005</u> until: <u>2/12/2006</u> </div> <div style="display: flex; justify-content: space-between; margin-top: 5px;"> <div style="text-align: center; font-size: x-small;">Date</div> <div style="text-align: center; font-size: x-small;">Date</div> </div> The fee for the amendment and extension of time has been calculated as shown below:						
CLAIMS AS AMENDED						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	57 -	130 =	0	x \$50.00	\$0.00	
INDEP. CLAIMS	5 -	5 =	0	x \$200.00	\$0.00	
FEE FOR AMENDMENT					\$0.00	
FEE FOR EXTENSION OF TIME					\$1,020.00	
TOTAL FEE FOR AMENDMENT AND EXTENSION OF TIME					\$1,020.00	

**COMBINED AMENDMENT & PETITION FOR EXTENSION OF
TIME UNDER 37 CFR 1.136(a) (Large Entity)**Docket No.
CRX113US

The fee for the amendment and extension of time is to be paid as follows:

- ☐ A check in the amount of _____ for the amendment and extension of time is enclosed.
- ☒ Please charge Deposit Account No. 07-1392 in the amount of \$1,020.00
- ☒ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No.
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☐ Any patent application processing fees under 37 CFR 1.17.
- ☐ If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



Signature

Virginia G. Campen, Reg. No. 37092

Dated: 23 Jan 2006

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

cc:

P28LARGE/REV05